CytomX Therapeutics (CTMX) EBITDA Margin (2014 - 2026)
CytomX Therapeutics posted quarterly EBITDA Margin of 177.98% for Q1 2026, down 22413.0% year-on-year from N/an in Q1 2025, and up 87.13% on a QoQ basis from 1382.5% in Q4 2025.
CytomX Therapeutics (CTMX) has 13 years of EBITDA Margin data on file, last reported at 177.98% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 22413.0% year-over-year to 177.98%; the trailing twelve-month figure through Mar 2026 stood at 117.33% (down 14553.0% YoY), and the FY2025 full-year result was 4.72%, down 2775.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 177.98%, up from 1382.5% in the prior quarter.
- Across five years, EBITDA Margin topped out at 49.52% in Q4 2024 and bottomed at 1382.5% in Q4 2025.
- The 5-year median for EBITDA Margin is 14.02% (2023), against an average of 151.29%.
- The widest annual swing landed in 2023, when EBITDA Margin soared 34724 bps; it then slumped 143202 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 39.61% in 2022, then jumped by 109 bps to 3.74% in 2023, then soared by 1224 bps to 49.52% in 2024, then plunged by 2892 bps to 1382.5% in 2025, then soared by 87 bps to 177.98% in 2026.
- The last three EBITDA Margin figures came in at 177.98% (Q1 2026), 1382.5% (Q4 2025), and 237.43% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | CytomX Therapeutics | 638.18 Mn | 291.48 Mn | - | -177.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.98% |
| Dec 31, 2025 | -1,382.50% |
| Sep 30, 2025 | -237.43% |
| Jun 30, 2025 | -0.64% |
| Mar 31, 2025 | 46.15% |
| Dec 31, 2024 | 49.52% |
| Sep 30, 2024 | 17.29% |
| Jun 30, 2024 | -25.99% |
| Mar 31, 2024 | 33.01% |
| Dec 31, 2023 | 3.74% |
| Sep 30, 2023 | 10.97% |
| Jun 30, 2023 | -4.36% |
| Mar 31, 2023 | -14.02% |
| Dec 31, 2022 | -39.61% |
| Sep 30, 2022 | -257.44% |
| Jun 30, 2022 | -231.38% |
| Mar 31, 2022 | -361.26% |
| Dec 31, 2021 | -315.46% |
| Sep 30, 2021 | -336.76% |
| Jun 30, 2021 | -303.33% |
| Mar 31, 2021 | -284.54% |
| Dec 31, 2020 | -339.02% |
| Sep 30, 2020 | -336.12% |
| Jun 30, 2020 | -366.61% |
| Mar 31, 2020 | 36.79% |
| Dec 31, 2019 | -798.36% |
| Sep 30, 2019 | -222.16% |
| Jun 30, 2019 | -319.80% |
| Mar 31, 2019 | -80.22% |
| Dec 31, 2018 | -279.99% |
| Sep 30, 2018 | -187.55% |
| Jun 30, 2018 | -135.32% |
| Mar 31, 2018 | -110.17% |
| Dec 31, 2017 | 2.17% |
| Sep 30, 2017 | -42.24% |
| Jun 30, 2017 | -288.23% |
| Mar 31, 2017 | -71.48% |
| Dec 31, 2016 | -224.27% |
| Sep 30, 2016 | -426.58% |
| Jun 30, 2016 | -456.56% |
| Mar 31, 2016 | -716.28% |
| Dec 31, 2015 | -581.24% |
| Sep 30, 2015 | -612.53% |
| Jun 30, 2015 | -283.75% |
| Mar 31, 2015 | -357.12% |
| Dec 31, 2014 | -257.23% |
| Sep 30, 2014 | -187.42% |